Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. We leverage our world-class delivery systems and related technologies to bring new medicines to patients who need them. We do this by selectively collaborating with leading pharma and biotech companies and fostering a culture of innovation that allows us to maintain our leadership position in the space. • Best-in-class LNP + next generation ligand conjugate technologies • First and only FDA-approved siRNA-LNP utilizes Genevant technology • Nucleic acid payload design expertise • Several hundred patents worldwide • LNP technology evaluated in more than a dozen clinical programs, representing hundreds of subjects and patients • An established leader in delivery to the liver, now focusing capabilities on other tissues and cell types • Experienced team with deep technical expertise and a track record of innovation and creative corporate partnering
Location: Canada, British Columbia, Vancouver
Employees: 11-50
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Roivant | roivant.co... |
Mentions in press and media 3
| Date | Title | Description |
| 14.01.2026 | TECregen Secures CHF 10 Million, Appoints Chairman to Propel Immune Rejuvenation | Swiss biotech TECregen secured CHF 10 million in seed funding. This investment propels its pioneering thymus-rejuvenating biologics. The goal: restore robust immune function, counter age-related decline, and tackle serious diseases. Boehrin... |
| 08.01.2026 | TECregen Raises CHF 10 Million Seed Round, Names Dr. Bo Rode Hansen Chairman | Basel, Switzerland-based TECregen has raised CHF 10 million (approximately €10.7 million / $12.6 million) in seed financing to advance a new class of thymus-rejuvenating biologics aimed at restoring immune function by rejuvenating thymic ep... |
| 24.10.2025 | Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore | The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics in October 2025 for individuals 6 months of age and older. SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- ... |